Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers Guidance
April 23, 2014 9:36 AM EDT
Wells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $87-$91. Analyst Brian Abrahams described Q1 results as "outstanding."
"On 4/22, GILD reported outstanding quarterly results, with Sovaldi sales likely exceeding most sell/buyside expectations, some... More
April 23, 2014 8:51 AM EDT
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Gilead Sciences (NASDAQ: GILD) and bumped his price target price target from $105 to $106 following impressive Q1 results and said the stock is officially a 'value' stock.
Schimmer comments, "GILD reported one of the... More
April 23, 2014 7:46 AM EDT
Goldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $65.00 (from $63.00).
Analyst Terence Flynn said, "Sovaldi posted an impressive beat in its first full quarter on the US market... More
April 23, 2014 7:39 AM EDT
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) from $121 to $130 calling Q1 'as good as it gets.'
We are raising our HCV sales estimates and target price to $130 from $121 following... More
